021 CD40L/IL-4 Ratio: A Potential Indicator of Therapeutic Response to a Shortened Topical Corticotherapy Strategy Combined to Ustekinumab in Bullous Pemphigoid

IF 5.7 2区医学 Q1 DERMATOLOGY

Journal of Investigative Dermatology Pub Date : 2024-11-20 DOI:10.1016/j.jid.2024.10.026

V. Koliadenko , F. Lemaire , P. Joly , C. Bedane , S. Ingen-Housz-Oro , A. Lopes , D. Giusti , S. Potteaux , S. Le Jan , M. Viguier

引用次数: 0

查看原文本刊更多论文

021 CD40L/IL-4 比率：大疱性类天疱疮患者对缩短局部皮质激素治疗策略联合乌司替库单抗治疗反应的潜在指标

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Investigative Dermatology 医学-皮肤病学

CiteScore

8.70

自引率

4.60%

发文量

1610

审稿时长

2 months

期刊介绍： Journal of Investigative Dermatology (JID) publishes reports describing original research on all aspects of cutaneous biology and skin disease. Topics include biochemistry, biophysics, carcinogenesis, cell regulation, clinical research, development, embryology, epidemiology and other population-based research, extracellular matrix, genetics, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, percutaneous absorption, pharmacology, photobiology, physiology, skin structure, and wound healing